Pharvaris (PHVS) Valuation Check After Positive Deucrictibant Phase 2 And RAPIDe 3 Results

Simply Wall St.

Mar 03

Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2616329691"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2616329691\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2616329691?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-03 22:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616329691","market":"hk","top_or_hot":-1,"title":"Pharvaris (PHVS) Valuation Check After Positive Deucrictibant Phase 2 And RAPIDe 3 Results","media":"Simply Wall St.","content":"<div>\n<p>Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris (PHVS) Valuation Check After Positive Deucrictibant Phase 2 And RAPIDe 3 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris (PHVS) Valuation Check After Positive Deucrictibant Phase 2 And RAPIDe 3 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-03 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant","article_id":"2616329691","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phvs/pharvaris/news/pharvaris-phvs-valuation-check-after-positive-deucrictibant","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2616329691","pubTimestamp":1772548065,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring fresh clinical evidence around both prophylactic and on-demand use.\nSee our latest analysis for Pharvaris.\nThe latest deucrictibant data arrives after a powerful run in Pharvaris’ total shareholder return, with an 82.77% 1 year gain and a very large 3 year payoff. The recent 90 day share price return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","PHVS":"Pharvaris N.V.","BK4007":"制药"},"translate_title":"Deucrictibant 2期和RAPIDe 3结果呈阳性后的Pharvaris(PHVS)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"PHVS":1.5},"content_text":"Pharvaris (NasdaqGS:PHVS) is back in focus after releasing final Phase 2 CHAPTER-1 open-label extension data and detailed RAPIDe-3 results for deucrictibant in hereditary angioedema, underscoring fresh clinical evidence around both prophylactic and on-demand use. See our latest analysis for Pharvaris. The latest deucrictibant data arrives after a powerful run in Pharvaris’ total shareholder return, with an 82.77% 1 year gain and a very large 3 year payoff. The recent 90 day share price return of 16.09% suggests momentum has been building into the AAAAI updates and ongoing late stage programs. If this kind of biotech catalyst is on your radar, it might be a good time to scan our list of 28 healthcare AI stocks as potential next ideas to research. With shares up 82.77% over 1 year and trading at US$28 against an average analyst target of about US$46, the key question is whether Pharvaris still offers upside or if markets are already pricing in future growth. AdvertisementPrice to Book of 5x: Is it justified? On Simply Wall St's numbers, Pharvaris screens as good value compared to its direct peers, trading on a 5x P/B multiple versus a peer average of 7.5x, even though the shares sit at $28. P/B compares the market value of the equity to the accounting book value, so for a pre revenue biotech like Pharvaris it is essentially a read on how the market is pricing the balance sheet and future optionality. A 5x P/B usually reflects investors placing a premium on a company that is still loss making, with limited current revenue and an asset base driven by R&D and cash rather than established products. Where it gets tricky is that the same 5x P/B multiple also looks expensive versus the broader US pharmaceuticals group, which sits at 2.2x. That contrast suggests investors are assigning Pharvaris a richer valuation than the wider industry, even though it is unprofitable, has reported a loss of $163.72m and is not forecast to generate revenue or reach profitability over the next three years. For anyone comparing it to sector averages, the market is clearly paying up for the pipeline story rather than current financials. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-Book of 5x (OVERVALUED) However, you still have to weigh the clear clinical execution risk in late stage trials, as well as the fact that Pharvaris remains pre revenue with a US$163.72m annual loss. Find out about the key risks to this Pharvaris narrative. Another View: Our DCF model suggests a very different price While the 5x P/B ratio pointed to an overvaluation risk, our DCF model shows almost the opposite. Pharvaris is trading at about 90.5% below an estimated fair value of roughly $296 per share. The gap is huge, so which signal do you think deserves more weight? Look into how the SWS DCF model arrives at its fair value. PHVS Discounted Cash Flow as at Mar 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Pharvaris for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 45 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If this mix of signals leaves you on the fence, it makes sense to move quickly, review the numbers yourself, and weigh both sides of the story, starting with 1 key reward and 3 important warning signs. Looking for more investment ideas? If this update has sharpened your focus, do not stop here. Use the Simply Wall St screener to spot other opportunities before the crowd does.  Target potential mispricings by checking our list of 45 high quality undervalued stocks that could offer more compelling entry points than higher expectation names. Strengthen the income side of your portfolio by reviewing 13 dividend fortresses that pair higher yields with an emphasis on resilience. Cut down on sleepless nights by scanning 76 resilient stocks with low risk scores that score well on stability and downside protection.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}